Toronto--Although few published studies exist on the prevention of thromboembolic disorders in urologic surgery, the risk of such disorders appears to be similar to that seen in other major surgical procedures.Therefore, urologists should concentrate on identifying patients at sufficient risk to warrant routine thromboprophylaxis, said the co-author of a new set of antithrombotic guidelines from the American College of Chest Physicians.
Jessica Feehan, NP-C, discusses the expanding role of APPs in urology, from clinical leadership and procedures to care coordination and treatment initiation.
Sam S. Chang, MD, MBA, discusses treatment selection after BCG failure, including bladder-sparing options, cystectomy considerations, and the need for sequencing data.
Justin B. Ziemba, MD, discusses clinical factors that help identify patients at increased risk for kidney stone recurrence and guide metabolic evaluation.
Adam Sharp, PhD, BM, MRCP, BSc, discusses preliminary safety and efficacy findings from a phase 1/2 study of gedatolisib plus darolutamide in patients with mCRPC.